Pubblicazioni scientifiche sui diagnostici non invasivi BioPredictive
Studi sottoposti a revisione paritaria che convalidano i diagnostici ematici BioPredictive per le malattie del fegato — dalle coorti di sviluppo pionieristiche alle meta-analisi a lungo termine.
132/435 Pubblicazioni
-
Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference. Key publication
-
Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.
-
Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Key publication
-
Toward non-invasive assessment strategies in autoimmune hepatitis.
-
The Diagnostic Value of FibroTest and Hepascore as Non-Invasive Markers of Liver Fibrosis in Primary Sclerosing Cholangitis (PSC).
-
Validation of the new 2021 EASL algorithm for the noninvasive diagnosis of advanced fibrosis in NAFLD.
-
Evolution of Non-alcoholic Fatty Liver Disease (NAFLD) Biomarkers in Response to Weight Loss 1 Year After Bariatric Surgery-a Post Hoc Analysis of the FibroTest Prospective Study. Key publication
-
Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. Key publication
-
The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis.
-
The impact of bariatric surgery on nonalcoholic fatty liver disease as measured using non-invasive tests.
-
Defining the Minimum Acceptable Diagnostic Accuracy of Noninvasive Fibrosis Testing in Cirrhosis: A Decision Analytic Modeling Study.
-
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. Key publication
-
Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study.
-
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. Key publication
-
Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study.
-
Impact of steatosis and inflammation definitions on the performance of NASH tests.
-
Childhood/adult-onset lysosomal acid lipase deficiency: A serious metabolic and vascular phenotype beyond liver disease-four new pediatric cases.
-
Interferon-γ-inducible protein-10 in chronic hepatitis C: Correlations with insulin resistance, histological features & sustained virological response.
-
Letter: APRI and FIB-4 do not correlate with Fibrosure in the evaluation of liver fibrosis in hepatitis C patients.
-
Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Call to Action. Review
-
Predictive value of biomarkers of hepatic fibrosis in adult Fontan patients.
-
Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review.
-
Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease.
-
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference. Key publication
-
Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers.
-
Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. Review
-
Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt.
-
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Key publication
-
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection
-
Liver fibrosis in adults with Fontan palliation: Do common screening studies predict disease severity?
-
Noninvasive Assessment of Liver Fibrosis.
-
Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience.
-
Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.
-
Study of FibroTest and hyaluronic acid biological variation in healthy volunteers and comparison of serum hyaluronic acid biological variation between chronic liver diseases of different etiology and fibrotic stage using confidence intervals.
-
Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease.
-
Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis.
-
[Diagnostic value of FibroTest for liver fibrosis in patients with chronic hepatitis B].
-
Biopsy as well as FibroTest/Fibrosure is suboptimal for discriminating intermediate fibrosis stages in patients with chronic hepatitis B.
-
Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C.
-
Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration.
-
FibroSURE as a noninvasive marker of liver fibrosis and inflammation in chronic hepatitis B.
-
Liver fibrosis markers in alcoholic liver disease. Review
-
Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey.
-
Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C.
-
The use of transient elastography and FibroTest for monitoring hepatotoxicity in patients receiving methotrexate for psoriasis.
-
[The value of noninvasive serological markers in hepatitis B]. Review
-
Commentary: prognostication of chronic hepatitis B--are Fibrotest and Fibroscan the final answers?
-
Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C.
-
Development and validation of a nomogram based on clinical factors and standard laboratory tests for prediction of clinically significant liver fibrosis in chronic hepatitis C virus infection.
-
Discordance between liver biopsy and FibroTest in assessing liver fibrosis in chronic hepatitis B.
-
Evaluation of liver stiffness measurement by fibroscan as compared to liver biopsy for assessment of hepatic fibrosis in children with chronic hepatitis C.
-
Improved inflammatory activity with peginterferon alfa-2b maintenance therapy in non-cirrhotic prior non-responders: a randomized study.
-
Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation.
-
Liver fibrosis: noninvasive assessment with acoustic radiation force impulse elastography--comparison with FibroScan M and XL probes and FibroTest in patients with chronic liver disease.
-
Non-invasive tests for fibrosis and liver stiffness predict 5-year survival of patients chronically infected with hepatitis B virus.
-
Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C.
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.
-
Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C.
-
Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C.
-
EASL clinical practical guidelines: management of alcoholic liver disease.
-
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.
-
Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
-
Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis.
-
Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography.
-
Non-invasive diagnostic assessment tools for the detection of liver fibrosis in patients with suspected alcohol-related liver disease: a systematic review and economic evaluation.
-
Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study.
-
Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard.
-
Twenty-year protocol liver biopsies: Invasive but useful for the management of liver recipients.
-
Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients.
-
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population.
-
A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Review
-
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
-
Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.
-
Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
-
FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC³ program.
-
First-line assessment of patients with chronic liver disease with non-invasive techniques and without recourse to liver biopsy.
-
Non-invasive markers for hepatic fibrosis. Review
-
Noninvasive Markers of Hepatic Fibrosis in Chronic Hepatitis B.
-
Noninvasive assessment of portal hypertension in patients with cirrhosis. Review
-
Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C.
-
Performance of the FibroTest cannot be accurately estimated in nine paediatric patients with advanced fibrosis.
-
Predicting significant fibrosis in hepatitis C patients in Luxembourg using serological markers.
-
Proficiency of transient elastography compared to liver biopsy for the assessment of fibrosis in HIV/HBV-coinfected patients.
-
Prognostic value of liver fibrosis biomarkers: a meta-analysis.
-
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases.
-
Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Meta Analysis
-
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.
-
Comparison of FibroTest-ActiTest with histopathology in demonstrating fibrosis and necroinflammatory activity in chronic hepatitis B and C.
-
Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso.
-
Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C.
-
Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Key publication
-
Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C.
-
Non-invasive assessment of liver fibrosis progression in hepatitis C patients retreated for 96 weeks with antiviral therapy: a randomized study.
-
Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest.
-
Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. Key publication
-
Optimization and robustness of blood tests for liver fibrosis and cirrhosis.
-
The role of the non-invasive serum marker FibroTest-ActiTest in the prediction of histological stage of fibrosis and activity in children with naïve chronic hepatitis B infection.
-
Appropriate evidence-based data overviews demonstrate the diagnostic and prognostic performances of FibroTest in patients with chronic hepatitis C.
-
Assessment of liver fibrosis in transplant recipients with recurrent HCV infection: usefulness of transient elastography.
-
Combination of fibrosis tests: sequential or synchronous?
-
Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Key publication
-
Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores.
-
Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02.
-
Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Review
-
Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Key publication
-
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C.
-
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B.
-
Assessment of liver fibrosis: noninvasive means.
-
Discordance between biochemical markers of liver activity and fibrosis (Actitest-Fibrotest) and liver biopsy in patients with chronic hepatitis C.
-
Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests.
-
FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Key publication Meta Analysis
-
Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients.
-
Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases.
-
Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C.
-
Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C.
-
FibroMAX: towards a new universal biomarker of liver disease? Review
-
Fibrotest-Actitest: the biochemical marker of liver fibrosis--the Israeli experience.
-
Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C.
-
The FibroTest value in discriminating between insignificant and significant fibrosis in chronic hepatitis C patients. The Romanian experience.
-
Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Key publication
-
Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
-
Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies.
-
Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease.
-
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.
-
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.
-
Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin.
-
Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients.
-
Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. Key publication
-
Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
-
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Key publication
-
Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic interest.
-
A simple biological index for detection of alcoholic liver disease in drinkers.
Mostra l'elenco completo dei risultati. La pagina è renderizzata sul server e non è paginata.